These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy. Venugopal S; Watts J Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):192-197. PubMed ID: 38066868 [TBL] [Abstract][Full Text] [Related]
27. New treatment for acute myelogenous leukemia. DiNardo CD; Cortes JE Expert Opin Pharmacother; 2015 Jan; 16(1):95-106. PubMed ID: 25480777 [TBL] [Abstract][Full Text] [Related]
28. Current and emerging therapies for acute myeloid leukemia. Robak T; Wierzbowska A Clin Ther; 2009; 31 Pt 2():2349-70. PubMed ID: 20110045 [TBL] [Abstract][Full Text] [Related]
29. [Progress in molecularly targeted therapies for acute myeloid leukemia]. Tomita A Rinsho Ketsueki; 2015 Feb; 56(2):130-8. PubMed ID: 25765792 [TBL] [Abstract][Full Text] [Related]
30. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility. Hou HA; Tien HF Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100 [TBL] [Abstract][Full Text] [Related]
31. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Reikvam H; Kittang AO; Melve G; Mosevoll KA; Bentsen PT; Ersvær E; Gjertsen BT; Bruserud Ø Curr Cancer Drug Targets; 2013 Jan; 13(1):30-47. PubMed ID: 22873213 [TBL] [Abstract][Full Text] [Related]
32. Conventional chemotherapy or hypomethylating agents for older patients with acute myeloid leukaemia? Ferrara F Hematol Oncol; 2014 Mar; 32(1):1-9. PubMed ID: 23512815 [TBL] [Abstract][Full Text] [Related]
33. The rocky road to personalized medicine in acute myeloid leukaemia. Brinda B; Khan I; Parkin B; Konig H J Cell Mol Med; 2018 Mar; 22(3):1411-1427. PubMed ID: 29327808 [TBL] [Abstract][Full Text] [Related]
34. DNA methylation as a pathogenic event and as a therapeutic target in AML. Schoofs T; Müller-Tidow C Cancer Treat Rev; 2011; 37 Suppl 1():S13-8. PubMed ID: 21612874 [TBL] [Abstract][Full Text] [Related]
35. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Stahl M; Gore SD; Vey N; Prebet T Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602 [TBL] [Abstract][Full Text] [Related]
36. Management of primary refractory acute myeloid leukemia in the era of targeted therapies. McMahon CM; Perl AE Leuk Lymphoma; 2019 Mar; 60(3):583-597. PubMed ID: 30234399 [TBL] [Abstract][Full Text] [Related]
37. Targeting the Amaya ML; Pollyea DA Clin Cancer Res; 2018 Oct; 24(20):4931-4936. PubMed ID: 29769206 [TBL] [Abstract][Full Text] [Related]
38. Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations. Devillier R; Gelsi-Boyer V; Brecqueville M; Carbuccia N; Murati A; Vey N; Birnbaum D; Mozziconacci MJ Am J Hematol; 2012 Jul; 87(7):659-62. PubMed ID: 22535592 [TBL] [Abstract][Full Text] [Related]
40. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia. Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]